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tween histological subtypes. Three-year survival was 72% 
for CYFRA 21-1 levels  1 3.3 ng/ml versus 75% for levels  ^  3.3 
ng/ml, 71% for CEA  1 6.7 ng/ml versus 75% for CEA  ^  6.7 ng/
ml (both p values  1 0.05). Corresponding 5-year survival rates 
were near 64% both for patients with CYFRA 21-1 values 
above and below the cutoff (3.3 ng/ml), and 49 and 66% for 
patients with values above and below the CEA cutoff (6.7 
ng/ml), respectively (both p values  1 0.05). Overall survival 
did not vary in the different TMI risk groups (p = 0.73).  Con-
clusions: In this cohort of early-stage NSCLC patients, male 
gender and age  1 70 years were associated with a worse out-
come, but elevated levels of CEA and CYFRA 21-1, and TMI 
risk were not.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 With over one million deaths in 2002  [1] and over 
160,000 in the United States (US) alone in 2005  [2] , lung 
cancer remains one of the leading causes of death world-
wide. Resection is still the only therapy recommended to 
treat stage I non-small cell lung cancer (NSCLC) by the 
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 Abstract 
 Objective: To validate the prognostic value of preoperative 
levels of CYFRA 21-1, CEA and the corresponding tumor 
marker index (TMI) in patients with stage I non-small cell 
lung cancer (NSCLC).  Methods: Two hundred forty stage I 
NSCLC patients (80 in pT1 and 160 in pT2; 100 squamous cell 
carcinomas, 91 adenocarcinomas, 32 large-cell carcinomas, 
17 with other histologies; 171 males and 69 females) who had 
complete resection (R0) between 1986 and 2004 were in-
cluded in the analysis. CYFRA 21-1 and CEA were measured 
using the Elecsys system (Roche) and AxSym-System (Ab-
bott), respectively. Univariate analysis was performed using 
the Kaplan-Meier method to identify potential associations 
between survival and age, gender, CYFRA 21-1, CEA and TMI. 
 Results: Overall 3- and 5-year survival rates were 74 and 
64%, respectively. Male gender (p = 0.0009) and age  1 70 
years (p = 0.0041) were associated with a worse prognosis; 
there were no differences between pT1 and pT2 nor be-
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International Union against Cancer  [3, 4] , with only few 
studies demonstrating a potential benefit of adjuvant 
platinum-based chemotherapy for stage IB  [5, 6] . There-
fore, a current challenge in NSCLC treatment is to iden-
tify patients that might benefit from more aggressive 
therapy versus those that may be overtreated. In addition 
to standard risk factors, in a study by Muley et al.  [7] 
elevated levels of oncological biomarkers (CEA and
CYFRA 21-1) were associated with a worse outcome in 
stage I NSCLC patients. Muley et al.  [7] therefore pro-
posed a prognostic score, the tumor marker index (TMI), 
comprising normalized CEA and CYFRA 21-1 values, 
and defined three prognostic groups based on the in-
creasing mortality risk according to the TMI score. They 
concluded that stage I NSCLC patients in the group with 
the worst prognosis according to the TMI might benefit 
from further therapy beyond surgery alone. Such a prog-
nostic score is desirable for stage I NSCLC patients since 
even in patients at this early stage, prognosis is poor, with 
a 5-year survival rate of approximately 60%. Against this 
backdrop, the aim of this study was to verify the results 
reported by Muley et al.  [7] and to validate the TMI in an 
independent cohort of patients.
 Patients and Methods 
 Patients 
 Preoperative data and clinical follow-up of 240 patients diag-
nosed with NSCLC in pathological stage I and treated between 
1986 and 2004 by complete resection (R0) at the University of Mu-
nich Hospital in Grosshadern, Munich, were included in the ret-
rospective study. In addition to pT stage and histology, data from 
CEA and CYFRA 21-1 levels determined within 30 days prior to 
surgery were required for inclusion in the study. Patients with 
known malignancies from other organs were excluded. The diag-
nosis of lung cancer was confirmed by pathological examination 
and classified according to the World Health Organization crite-
ria  [8] . Postoperative tumor stage was defined by the revised In-
ternational System for staging of Lung Cancer  [9] .
 Tumor-Associated Antigens 
 Blood samples were taken within 30 days prior to surgery. 
CEA was determined with an Abbott AxSYM Analyzer (Abbott 
Laboratories, Chicago, Ill., USA) using the microparticle enzyme 
immunoassay. Starting from 1992, CYFRA 21-1 was routinely as-
sessed by an Elecsys kit (Roche Diagnostics, Mannheim, Germa-
ny) in all patients with suspected lung cancer. In patients treated 
before 1992, serum samples stored at –80 ° C were used for CYFRA 
21-1 determination.
 TMI 
 In the study by Muley et al. [7] , CYFRA 21-1 and CEA were 
both assessed by the Cobas Core System of Roche Diagnostics. 
The TMI was defined by taking the geometric mean of normal-
ized values of CYFRA 21-1 and CEA, where normalization was 
performed by dividing individual marker values by correspond-
ing diagnostic cutoff points, i.e. 3.3 ng/ml for CYFRA 21-1 and 5.0 
ng/ml for CEA:
CYFRA21-1ng/ml CEA ng/ml
TMI
3 3 ng/ml 5 0 ng/ml. .
 
 In this study, TMI was calculated accordingly with the excep-
tion of using 4.0 ng/ml as the normalizing factor for CEA due to 
the different assay system; this was not necessary for CYFRA
21-1 since the Elecsys system employs the same diagnostic cutoff 
point.
 Statistical Analysis 
 Univariate Kaplan-Meier survival curves and rates were cal-
culated, with statistical significance assessed using the log-rank 
test. To be able to compare our results with those of Muley et al. 
 [7] , the cutoff points for age and CYFRA 21-1 were 70 years and 
3.3 ng/ml, respectively, and the same three risk groups for TMI 
were assessed:  ! 0.48 for group A (low risk), 0.48–0.83 for group 
B (intermediate risk) and  1 0.83 for group C (high risk). Due to 
the use of different CEA assays, the cutoff point for CEA was 6.7 
ng/ml as opposed to 9.8 ng/ml in the study by Muley et al. [7] in 
order to achieve the same percentage of patients with CEA values 
above the cutoff point (13%). In addition, for CYFRA 21-1 and 
CEA, all values between the 5th and 95th percentiles were evalu-
ated as potential cutoff points using the log-rank test, with statis-
tical significance being assessed at the down-adjusted level of   = 
0.0017, as recommended for multiple testing  [10] . All other statis-
tical tests were performed at the two-sided   = 0.05 level of statis-
tical significance. All analyses were performed using the statisti-
cal package of SAS (version 9.1, SAS, Cary, N.C., USA).
 Results 
 The characteristics of the 240 study patients and those 
of the study by Muley et al.  [7] are given in  table 1 . Their 
study comprised 153 stage I patients, all treated surgi-
cally (R0) between 1996 and 1998 at the Clinic for Tho-
racic Diseases of the University of Heidelberg.  Table 1 
shows that patient characteristics did not differ between 
both studies (all p  1 0.05).
 The 3- and 5-year overall survival rates did not sig-
nificantly differ between our (74 and 64%, respectively), 
and their study (75 and 58%, respectively;  table 2 ). Me-
dian survival of female patients was 13 years, and in males 
survival was statistically significantly shorter. Age  1 70 
years was also associated with a poorer outcome. There 
were neither statistically significant differences in sur-
vival between pT1 and pT2 stage patients or between his-
tological subtypes nor between adenocarcinomas and 
squamous cell carcinomas, in agreement with the study 
by Muley et al. ( table 2 ).
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 Table 3  lists  tumor marker levels in their and our
study groups, and in our patients according to pT stage. 
CYFRA 21-1 levels were similar in both studies, whereas 
CEA levels were lower in our study due to the different 
assay system used. Marker levels were higher in pT2 com-
pared to pT1 stage patients.
 Three- and 5-year survival rates for preoperative
CYFRA 21-1 and CEA levels of patients grouped accord-
ing to the cutoff points are described in  table 4 . Based on 
these cutoff points, neither CYFRA 21-1 nor CEA was as-
sociated with survival (p = 0.67 for CYFRA 21-1 and p = 
0.09 for CEA). In contrast, a significant association be-
tween CYFRA 21-1 and 3-year survival was reported in 
the study by Muley et al. (p = 0.015), with a markedly 
lower 3-year survival rate for patients with CYFRA 21-1 
levels above the cutoff point compared with this study 
( table 4 ).
 TMI was calculated for all of our patients according to 
the risk groups described by Muley et al.  [7] . In their 
study, the low-, intermediate- and high-risk groups com-
Table 1. Characteristics of the lung cancer patients from Munich 
and Heidelberg
Characteristics Munich
(n = 240)
Heidelberg
(n = 153a)
p
valueb
Age, years
Mean 63.6 64.8
Range 23–81 32–78
Male 171 (71.2%) 121 (79.1%) 0.08Female 69 (28.8%) 32 (20.9%)
Squamous cell carcinoma 100 (41.7%) 59 (38.6%)
0.07Adenocarcinoma 91 (37.9%) 75 (49%)Large-cell carcinoma 32 (13.3%) 10 (6.5%)
Other histologies 17 (7.1%) 9 (5.9%)
pT1 stage 80 (33.3%) 51 (33.3%) 1.00pT2 stage 160 (66.6%) 102 (66.6%)
Died during follow-up
Total 111 (46.3%) not reported
Male 88 (36.7%) not reported
Female 23 (17%) not reported 
a Extracted from Muley et al. [7].
b 2 test for differences between the two studies.
Table 2. Univariate analysis of survival
Median
survival
months
Munich Heidelberg
p value
log-rank test5-yearsurvival, %
3-year
survival, %
p value
log-rank test
Overall 110 63.9 74.4
Sex <0.001 0.029
Male 86 58.0 70.4
Female 156 76.7 83.5
Age 0.004 0.026
<70 years 125 69.6 77.8
>70 years 58 47.6 64.1
Histological type 0.16 0.18
Squamous cell carcinoma 105 64.5 72.0
Adenocarcinoma 125 63.2 76.7
Large cell carcinoma 61 55.6 65.4
Other histology 123 77.9 92.9
Pathological stage 0.146 0.14
pT1 125 71.5 81.1
pT2 96 59.9 70.9
Table 3. Distribution of biomarkers (ng/ml)
Munich (n = 240) Heidelberg (n = 153)
n median (5th–95th 
percentiles)
n median (5th–95th 
percentiles)
CYFRA 21-1
All 240 1.8 (0.9–7.5) 141 1.8 (0.9–8.0)
pT1 80 1.2 (0.5–3.2) not reported
pT2 160 2.6 (0.5–13.2) not reported
CEA
All 240 2.7 (0.9–13.8) 153 3.5 (1.1–21.0)
pT1 80 2.6 (0.9–8.6) not reported
pT2 160 2.8 (0.9–25.5) not reported
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prised 22.7, 42.6 and 34.7% of the patients, respectively, 
showing statistically significant differences in survival 
rates ( table 4 ). Neither CEA or CYFRA 21-1 levels nor 
TMI were statistically significant in this study (p = 0.7320; 
 fig. 1 ;  table 4 ). Therefore, alternative cutoff points for
CYFRA 21-1 and CEA were investigated to independent-
ly assess the prognostic information of these biomarkers. 
For CYFRA 21-1 none of the cutoff points indicated prog-
nostic value at the adjusted 0.0017 level of statistical sig-
nificance ( fig. 2 ). This was also true when only squamous 
cell carcinomas and adenocarcinomas were analyzed. 
CEA cutoff points  6 9 ng/ml indicated statistical signifi-
cance at the adjusted   level (p = 0.0015). However,  ! 10% 
of the patients had CEA levels above this cutoff point 
( fig. 3 ). For CEA, no other significant cutoff points were 
found restricting the patient group to adenocarcinomas 
or squamous cell carcinomas.
Table 4. Univariate analysis of survival and biomarkers (ng/ml)
Median
survival
months
Munich Heidelberg
5-year
survival, %
3-year
survival, %
p
value
3-year
survival, %
p value
CYFRA 21-1 0.67 0.015
>Cutoff point 102 64 72.3 60.2
≤Cutoff point 110 63.8 74.9 78.4
CEA 0.09 0.014
>Cutoff point 59 49 70.8a 41.6b
≤Cutoff point 110 66.1 74.9a 79.2b
TMI 0.73
High-risk group 105 63.1 75.9 55.7 0.0008 vs. low
Intermediate-risk group 110 63.5 75.0 77.2 0.077 vs. high
Low-risk group 122 65.1 72.1 96.7 0.017 vs. low
Cutoff point for CYFRA 21-1: 3.3 ng/ml.
a Cutoff point: 6.7 ng/ml. b Cutoff point: 9.8 ng/ml.
0
20
40
<0.48
<0.48 82 76 63 48 39 35 32 28 25 21 14
87 78 68 54 47 42 39 33 26 19 15
71 62 52 45 38 32 26 22 17 15 11
p = 0.7320
log-rank
>0.83
>0.83
0.48–0.83
0.48–0.83
Patients at risk: 0 1 2 3 4 5 6 7 8 9 10
60
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iv
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 (%
)
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 Fig. 1. Survival curves by TMI. 
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 Discussion 
 Survival rates for patients suffering from NSCLC are 
dismal, even for early-stage disease. While surgery is cur-
rently the only treatment recommended for NSCLC, evi-
dence accumulates that some patients might benefit from 
adjuvant therapy  [11, 12] . Prognostic factors such as the 
TMI might help to separate patients likely to benefit from 
adjuvant therapy from those who have a good prognosis 
postoperatively.
 Overall survival rates in this study (74% for 3 years and 
64% for 5 years) were similar to those reported by Muley 
et al. [7] and others  [13–16] . Two studies reported a sur-
vival rate of approximately 80% at 5 years  [17, 18] , but 
these studies had a higher percentage of female patients 
and in one of them  [18] , patient follow-up was only 36 
months versus 110 months in our study. The previously 
established prognostic factors age and sex  [7, 13, 17, 18] 
were confirmed in this investigation, whereas tumor size 
or histology were not associated with survival, in accord 
with the results of Muley et al. [7] . However, the results of 
this study neither confirmed the association of TMI to 
survival nor the prognostic significance of CYFRA 21-1. 
In studies including patients with NSCLC at all stages 
 [19–22] or those restricted to patients with squamous cell 
carcinomas of the lung  [15, 23, 24] , high CYFRA 21-1 lev-
els have been associated with a poorer outcome indepen-
dent of histology. Most of them used clinical staging to 
diagnose early-stage NSCLC, leading to bias due to po-
tential misstaging  [17, 25–27] . To our knowledge, only 
two studies on CYFRA 21-1 and CEA levels have been 
conducted exclusively in pathological stage I patients  [7, 
18] . Muley et al.  [7] demonstrated independent signifi-
cant prognostic significance for CYFRA 21-1, and Mat-
suoka et al.  [18] revealed CYFRA 21-1 as a significant 
prognosticator for overall survival but not time to pro-
gression.
 Although CEA is one of the earliest available biomark-
ers, its role as a prognosticator for survival in NSCLC re-
mains controversial. The prognostic value of CEA was 
demonstrated in several studies  [7, 25, 26, 28] in contrast 
to others  [20, 29, 30] , which may be due to the heteroge-
neous histological subtypes. Investigations including a 
high percentage of patients with squamous cell carcino-
ma  [20, 24] found a statistically significant association 
between elevated preoperative CEA levels and poorer 
survival, whereas the study by Nisman et al.  [23] showed 
statistical significance only in patients with adenocarci-
noma. In our study, statistically significant associations 
between CEA and survival could only be demonstrated 
for preoperative CEA levels  1 9 ng/ml or on a continuous 
scale. The detection of prognostic significance depends 
on the cutoff point selected. Thus, more detailed exami-
nations covering a range of CEA cutoff points and scales 
may aid in the detection of associations. Findings from 
these investigations require external validation since data 
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 Fig. 2, 3. Evaluation of alternative cutoff points of CYFRA 21-1 ( 2 ) 
and CEA ( 3 ) for associations with mortality; solid curve: percent-
age of patients with values above the corresponding cutoff points; 
dashed curve: p values from log-rank test for each cutoff point; 
lower horizontal dashed line: p value of 0.05; upper horizontal 
line: adjusted p value  [10] . 
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mining of a particular dataset is used to identify the op-
timal cutoff point, with a high probability of not being 
exactly replicated in other studies. One reason for the dif-
ferences in the prognostic values of CYFRA and CEA 
found across studies could be the incomparability of im-
munoassays across different assay systems, which is par-
ticularly striking when selected cutoff points are used. 
For this reason, alternative cutoff points for CEA and 
CYFRA 21-1 to those recommended by Muley et al.  [7] 
were investigated in this study. Another limitation is the 
heterogeneity of the patient cohorts. These inconsisten-
cies should be resolved by further external validations, 
preferably across multiple centers.
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